#United States #National Harbor #CAR-T #AAVivo #biotherapy

AAVivo, Inc. to Present at Society for Immunotherapy of Cancer 2025

AAVivo, Inc., a pioneering company in the biotechnology sector, is gearing up to make a significant contribution to the field of cancer immunotherapy by presenting at the Society for Immunotherapy of Cancer (SITC) 2025. The event is scheduled to take place from November 5-9, 2025, in National Harbor, Maryland. This prominent conference brings together experts in oncology, providing a platform for cutting-edge research and innovative treatments.

The spotlight will be on AAVivo's groundbreaking work on a precision-targeted biotherapeutic known as AVO-100, designed for the treatment of B cell malignancies. A poster presentation focused on this novel gene therapy will showcase their findings on the in vivo generation of CD19-specific CAR-T cells using a novel adeno-associated virus (AAV) gene therapy platform. This approach is particularly noteworthy because it aims to create CAR-T cells directly within the body, minimizing the challenges associated with traditional CAR-T cell therapies.

Dr. Haifeng Chen, AAVivo's Chief Technology Officer and Founder, expressed enthusiasm about this recognition from SITC, stating, "We are pleased that a poster highlighting the potential of our iAAV platform to rapidly enable in vivo generation of CAR-T cells was accepted for presentation at SITC 2025. This underscores the potential impact of our technology on cancer treatment."

The poster will detail the preclinical results that indicate AVO-100’s ability to generate CD19-specific T cells from non-activated T cells found in human peripheral blood mononuclear cells (PBMCs), both in vitro and in vivo. Additionally, the CAR-T cells generated have shown promise in controlling the growth of Raji lymphoma tumors in laboratory settings, indicating a potential breakthrough for patients battling such malignancies.

AAVivo's iAAV-based platform is a significant advancement in the gene therapy landscape. This proprietary technology facilitates the in vivo generation of CAR-T cells, which could transform the therapeutic approach to treating various forms of cancer. In addition to AVO-100, AAVivo's pipeline includes promising candidates like AVO-200 and AVO-300, aimed at tackling solid tumors, further solidifying the company's role as a leader in gene therapy.

Key technologies supporting AAVivo's innovation include:

• - BAC-to-AAV Technology: This method allows for large-scale, cost-effective manufacturing of adeno-associated viruses, essential for widespread clinical application.
• - Precision AAV Capsid Engineering (PACE): This innovative engineering technique enhances the specificity of cell targeting, potentially leading to improved therapeutic outcomes.
• - Selective Toxin Packaging (SToP) Platform: This platform includes a microRNA safety shield to ensure safe and efficient delivery of therapeutic genes without the need for lymphodepletion, which is a common requirement in traditional CAR-T therapies.

The combination of these technologies presents a compelling argument for the scalability, efficacy, and safety of AAVivo's products. By addressing significant challenges in the gene therapy sector, AAVivo is poised to make a lasting impact on cancer treatment methodologies.

As AAVivo continues to advance its research and development, it presents unique opportunities for investors interested in innovative biotechnology solutions. The upcoming presentation at SITC 2025 not only highlights the rapid progress within AAVivo but also signifies a monumental step toward transforming cancer treatment.

For more information on AAVivo and its pioneering technologies, visit AAVivo's website.